Cargando…

Radionuclide therapy in the time of COVID-19

Detalles Bibliográficos
Autores principales:	Brabander, Tessa, Hofland, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297509/ https://www.ncbi.nlm.nih.gov/pubmed/32548661 http://dx.doi.org/10.1007/s00259-020-04921-9

Ejemplares similares

Peptide Receptor Radionuclide Therapy
por: Hofland, Johannes, et al.
Publicado: (2022)

Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy
por: Minczeles, N.S., et al.
Publicado: (2021)

A Clinical Guide to Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in Neuroendocrine Tumor Patients
por: Becx, Morticia N., et al.
Publicado: (2022)

Peptide Receptor Radionuclide Therapy With (177)Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
por: Zandee, Wouter T, et al.
Publicado: (2021)

Effect of epigenetic treatment on SST(2) expression in neuroendocrine tumour patients
por: Refardt, Julie, et al.
Publicado: (2022)

Comparison of [(18)F]DOPA and [(68)Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy
por: Veenstra, Emile B., et al.
Publicado: (2022)

Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls
por: Beukhof, Carolien M., et al.
Publicado: (2019)

From fixed activities to personalized treatments in radionuclide therapy: lost in translation?
por: Flux, G. D., et al.
Publicado: (2017)

Advances in (177)Lu-PSMA and (225)Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Ling, Sui Wai, et al.
Publicado: (2022)

Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy
por: Ebbers, Sander C., et al.
Publicado: (2022)

A perspective on the EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands
por: Gericke, Germo
Publicado: (2021)

Radionuclide molecular imaging of abdominal aortic aneurysms for risk stratification and non‐invasive therapy assessment
por: Gandhi, Richa, et al.
Publicado: (2021)

Bile leak detection after trauma by radionuclide scintigraphy
por: Mohan, Parul, et al.
Publicado: (2016)

Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
por: van der Zwan, W. A., et al.
Publicado: (2018)

SARS-CoV-2 vaccination and metabolic radionuclide therapy: Document of the SEMNIM Endocrinology Working Group()
por: Negre Busó, Montserrat, et al.
Publicado: (2021)

Update to “Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors”
por: Zhu, Mojun, et al.
Publicado: (2022)

Finding the right time for anti-inflammatory therapy in COVID-19
por: de Simone, Giovanni, et al.
Publicado: (2020)

Left lobe hypoplasia of thyroid with right lobe ectopia: Radionuclide thyroid scan and ultrasonographic correlation
por: Mohan, Parul, et al.
Publicado: (2016)

Is it necessary to do surgical fixation in metastatic bone disease impending pathologic fracture before (177)Lu-prostate-specific membrane antigen radionuclide therapy?
por: Assadi, Majid
Publicado: (2021)

Case work-up and monitoring of systemic radionuclide therapies: A proposed 3-sheet excel format with integrated graph for implementation in a busy treatment set-up
por: Loharkar, Sarvesh, et al.
Publicado: (2020)

It is time to consider an anti-inflammatory therapy based on the pathophysiology of COVID-19 infection during the right time window?
por: Ghanei, Mostafa
Publicado: (2021)

Is it time to move to systematic antithrombotic prophylaxis or therapy for all patients with COVID-19 disease?
por: Njonnou, Sylvain Raoul Simeni, et al.
Publicado: (2021)

Considering Personalized Interferon Beta Therapy for COVID-19
por: Dorgham, Karim, et al.
Publicado: (2021)

Prothrombosis in times of COVID-19
por: Pereiro Lili, Iñigo, et al.
Publicado: (2020)

Orthopaedics in Times of COVID 19
por: Bagaria, Vaibhav, et al.
Publicado: (2020)

No half-time for COVID-19
por: Lin, I-Cheng, et al.
Publicado: (2022)

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
por: da Silva, Tiago Nunes, et al.
Publicado: (2018)

Prehospital High-Flow Nasal Oxygen Therapy on COVID-19 Patients: An Additional Waiting Time
por: Cazes, Nicolas, et al.
Publicado: (2021)

Dual ectopic thyroid – noninvasive diagnosis on radionuclide thyroid scan with SPECT/CT correlation: A case report and brief review of literature
por: Joshi, Prathamesh Vijay, et al.
Publicado: (2013)

LGBTQ care at the time of COVID-19
por: Chatterjee, Subhankar, et al.
Publicado: (2020)

Commemoration of the Dead in the Time of COVID-19
por: G. Corpuz, Jeff Clyde
Publicado: (2021)

Medical education in COVID-19 times
por: Gupta, Harish
Publicado: (2023)

Romeo and Juliet: Revisited (at the time of COVID-19)
por: Costantino, Giorgio, et al.
Publicado: (2020)

Preserving the “human touch” in times of COVID-19
por: Sagar, Rajesh, et al.
Publicado: (2020)

COVID 19 and Surgical Education: Time for Innovations
por: Gupta, Nikhil, et al.
Publicado: (2020)

Cardiovascular Collateral Damages at the Time of COVID-19
por: Jacques, Frédéric, et al.
Publicado: (2020)

Orthopaedic Surgery in Times of COVID-19 in India
por: Majumdar, PK, et al.
Publicado: (2020)

Obesity and COVID-19: Time to Take Action
por: Akbas, Feray, et al.
Publicado: (2020)

Reumataxi: An experience of solidarity in times of COVID-19()
por: Blanch-Rubió, Josep, et al.
Publicado: (2022)

Teleconsultation of infant rheumatology in Covid-19 time()
por: Nieto-González, Juan Carlos, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pv3vbv8fogg7r889aue173sbmr